Revvity, Inc. (RVTY)
Data as of Nov 2, 4:03 PM ETPrices may be delayedHow our data works
Res / Sup are automatic swing levels for educational reference only — not signals or advice.
Prices may be delayed. For informational purposes only — not investment advice.
RVTY key stats
RVTY GlowScore: Active
A 0–100 read on today's activity from volume, momentum and intraday range. Not a buy or sell signal.
About Revvity, Inc.
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
What's moving RVTY today
Updated November 3, 2026As of November 3, 2026, Revvity, Inc. (RVTY) stock fell to $151.60, down 3.44% (-$5.40) versus the previous close. On the day, shares have traded between $150.63 and $160.07. That puts RVTY in the upper third of its 52-week range of $81.22 to $169.06. Revvity, Inc. operates in the laboratory analytical instruments space and carries a market capitalization of roughly $16.92 billion, with about 2.80 million shares changing hands.
Latest RVTY news
- Revvity (RVTY) Tops Q3 Earnings and Revenue EstimatesYahoo Finance· Nov 3, 6:25 AM ET
- Revvity (NYSE:RVTY) surprises with strong Q3 2026, stock soarsYahoo Finance· Nov 3, 6:24 AM ET
- Revvity: Q3 Earnings SnapshotYahoo Finance· Nov 3, 6:11 AM ET
- Cognex Gears Up to Report Q3 Earnings: What's in Store for the Stock?Yahoo Finance· Nov 2, 11:26 AM ET
- Fair Isaac to Report Q4 Earnings: What's in Store for the Stock?Yahoo Finance· Nov 2, 11:14 AM ET
- MKSI Gears Up to Report Q3 Earnings: What's in Store for the Stock?Yahoo Finance· Nov 2, 11:01 AM ET
- AMETEK to Post Q3 Earnings: Time to Buy, Sell or Hold the Stock?Yahoo Finance· Nov 2, 9:06 AM ET
- Bio-Techne's Q1 Earnings on Deck: What's in Store for the Stock?Yahoo Finance· Nov 2, 6:44 AM ET
Source: Yahoo Finance RSS · Updated November 3, 2026
Want RVTY headlines, alerts and AI research in one place? Create a free account →
RVTY buzz on Stocktwits
789 watchers$RVTY (+10.2% pre) Revvity (RVTY) Tops Q3 Earnings and Revenue Estimates https://ooc.bz/l/119651
@OpenOutcrier· Nov 3, 8:46 AM ET
Tuesday morning and biotech is shaking off a rough Monday imo $XBI closed Monday at 152.05, down 2.52%, and premarket is basically flat near 152.20. still under the 50 day near 156.33, still well above the 200 day near 141.72 $IBB closed at 213.79, down 1.76%, and premarket is…
@BiotechSwings· Nov 3, 8:25 AM ET
$RVTY Q3 '26 Earnings Results & Recap Revvity forecasts full year 2026 pro forma total revenue of approximately $2.86B, pro forma organic revenue growth of approximately 5%, and pro forma adjusted EPS of $5.40-$5.45.
@StocktwitsEarnings· Nov 3, 7:28 AM ET
@Cash4freedom $NTRA $RVTY $TWST ...
@MaverikIT· Nov 2, 8:29 AM ET
$RVTY what is Happening Here????
@benwick91· Oct 30, 4:42 PM ET
Source: Stocktwits. User posts are opinions, not verified facts. See what's trending →
RVTY Congress & insider trades
Congress amounts are the disclosed ranges; filings can lag the trade date by up to 45 days.
AI research on RVTY
Get an instant AI breakdown of the bull & bear case, key risks, and what analysts are watching.
Not financial advice. This page is for educational purposes only. Data comes from third-party sources, may be delayed or incomplete, and should not be the basis of any investment decision.